ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,601 to 4,620 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
MMRV (AMP) vs MMRV (2006 Process): serious adverse events21 of 682

18 of 683

0.4 points

-1.4 to 2.3

1,365NCT01536405

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

V181 vs Butantan - DV: deaths from any cause1 of 682

0 of 682

0.1 points

-0.4 to 0.8

1,364NCT05710224

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

Shared Decision Making/Brief Negotiated Interviewing vs Control Arm: serious adverse events5 of 678

0 of 684

0.7 points

0.0 to 1.7

1,362NCT02910089

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus

ESO 40 mg vs RAB ER 50 mg: serious adverse events6 of 676

3 of 685

0.4 points

-0.5 to 1.5

1,361NCT00658632

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Hydroxychloroquine vs Placebo: serious adverse events3 of 683

2 of 677

0.1 points

-0.7 to 1.0

1,360NCT04334148

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Sensitivity Analysis11 of 103

111 of 1,257

1.8 points

-3.1 to 9.4

1,360NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months- Sensitivity Analysis57 of 103

358 of 1,257

26.9 points

16.9 to 36.4

1,360NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Sensitivity Analysis27 of 103

301 of 1,257

2.3 points

-5.6 to 11.8

1,360NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Months- Sensitivity Analysis14 of 103

137 of 1,257

2.7 points

-2.9 to 10.8

1,360NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis76 of 103

976 of 1,257

-3.9 points

-13.4 to 4.0

1,360NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Sensitivity Analysis101 of 103

1,227 of 1,257

0.4 points

-4.5 to 2.2

1,360NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Intervention-hypo vs Control-standard Care: serious adverse events547 of 688

513 of 671

3.1 points

-1.4 to 7.5

1,359NCT00391469

Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest

Hydroxychloroquine vs Placebo: Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)7 of 683

8 of 676

-0.2 points

-1.4 to 1.1

1,359NCT04334148

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Hydroxychloroquine vs Placebo: Number of Participants With Clinical Infection With COVID-19 Infection41 of 683

53 of 676

-1.8 points

-4.6 to 0.9

1,359NCT04334148

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Hydroxychloroquine vs Placebo: Number of Participants With COVID-19 Viral Shedding2 of 683

2 of 676

-0.0 points

-0.8 to 0.8

1,359NCT04334148

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

MVI 200 vs Dinoprostone Vaginal Insert (DVI): serious adverse events130 of 678

107 of 680

3.4 points

-0.6 to 7.5

1,358NCT01127581

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

High Dose Vitamin D Formulation vs Placebo: serious adverse events14 of 690

18 of 668

-0.7 points

-2.4 to 1.0

1,358NCT03096314

Vitamin D to Improve Outcomes by Leveraging Early Treatment

V181 vs Butantan - DV: serious adverse events12 of 680

9 of 678

0.4 points

-1.0 to 1.9

1,358NCT05710224

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

Sustained Care vs Standard Care: Tobacco Abstinence - 6 Month Follow-up113 of 680

105 of 677

1.1 points

-2.8 to 5.0

1,357NCT01714323

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

Sustained Care vs Standard Care: All-cause Mortality13 of 680

14 of 677

-0.2 points

-1.7 to 1.4

1,357NCT01714323

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=231"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=231

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01536405-sae",
        "title": "MMRV (AMP) vs MMRV (2006 Process): serious adverse events",
        "summary": "21 of 682 against 18 of 683; risk difference 0.4 points, 95% interval -1.4 to 2.3; NCT01536405, Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)",
        "record": "/library/comparisons/NCT01536405-sae",
        "nct_id": "NCT01536405",
        "kind": "serious-adverse-events",
        "participants": 1365,
        "risk_difference": {
          "value": 0.004437469676217137,
          "lower": -0.013843021046426027,
          "upper": 0.022953996493854587
        },
        "group_1": "21 of 682",
        "group_2": "18 of 683",
        "difference": "0.4 points",
        "interval": "-1.4 to 2.3",
        "trial_title": "Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)"
      },
      {
        "id": "NCT05710224-deaths",
        "title": "V181 vs Butantan - DV: deaths from any cause",
        "summary": "1 of 682 against 0 of 682; risk difference 0.1 points, 95% interval -0.4 to 0.8; NCT05710224, Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)",
        "record": "/library/comparisons/NCT05710224-deaths",
        "nct_id": "NCT05710224",
        "kind": "deaths",
        "participants": 1364,
        "risk_difference": {
          "value": 0.001466275659824047,
          "lower": -0.004263471030847753,
          "upper": 0.008258333937551803
        },
        "group_1": "1 of 682",
        "group_2": "0 of 682",
        "difference": "0.1 points",
        "interval": "-0.4 to 0.8",
        "trial_title": "Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=232",
  "request_id": "kwfRZ7B22pecidbQ"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?